81212
document
Lisinopril administration improves insulin action in aged patients with hypertension . Thirty elderly , mildly hypertensive patients were enrolled for a single-blind , randomised cross-over placebo controlled trial in which placebo and lisinopril ( 20 mg/day before breakfast ) were given for 4 and 8 weeks , respectively . A wash-out period of 3 weeks between placebo and lisinopril was observed . In each patient a euglycaemic glucose clamp with simultaneous indirect calorimetry allowed us to determine whole body glucose disposal and substrate oxidation . Changes in morning SBP and DBP were also determined . Lisinopril vs. placebo significantly improved whole body glucose disposal ( 40.4 +/- 0.4 vs. 30.3 +/- 0.4 mumol/kg LBM x min ; P < 0.01 ) , non-oxidative glucose metabolism ( 18.1 +/- 0.7 vs. 10.9 +/- 0.6 mumol/kg LBM x min ; P < 0.01 ) and fasting plasma potassium levels ( 4.8 +/- 3 vs. 4.4 +/- 0.4 mmol/l ; P < 0.05 ) . SBP ( 175 +/- 3.3 vs. 160 +/- 3.0 mm Hg ; P < 0.001 ) and DBP ( 106 +/- 2.3 vs. 95 +/- 2.0 mm Hg ; P < 0.001 ) were significantly reduced by lisinopril administration . After ACE inhibition , fasting plasma potassium levels correlated with the decline in mean arterial BP ( r = -0.71 ; P < 0.006 ) . In conclusion , lisinopril administration reduces arterial BP and improves insulin sensitivity in elderly hypertensive patients .
81213
Intervention_Pharmacological
Lisinopril
81214
Intervention_Control
placebo
81215
Intervention_Control
placebo
81216
Intervention_Pharmacological
lisinopril
81217
Intervention_Control
placebo
81218
Intervention_Pharmacological
lisinopril
81219
Intervention_Pharmacological
Lisinopril
81220
Intervention_Control
placebo
81221
Intervention_Pharmacological
lisinopril
81222
Intervention_Pharmacological
lisinopril
81223
Outcome_Physical
insulin action
81224
Outcome_Physical
whole body glucose disposal
81225
Outcome_Physical
substrate oxidation
81226
Outcome_Other
Changes
81227
Outcome_Physical
morning SBP and DBP
81228
Outcome_Physical
whole body glucose disposal
81229
Outcome_Physical
non-oxidative glucose metabolism
81230
Outcome_Physical
fasting plasma potassium levels
81231
Outcome_Physical
SBP
81232
Outcome_Physical
DBP
81233
Outcome_Physical
fasting plasma potassium levels
81234
Outcome_Physical
decline in mean arterial BP
81235
Outcome_Physical
arterial BP
81236
Outcome_Physical
improves insulin sensitivity
81237
Participant_Age
aged
81238
Participant_Condition
patients with hypertension .
81239
Participant_Sample-size
Thirty
81240
Participant_Age
elderly
81241
Participant_Condition
mildly hypertensive
81242
Participant_Age
elderly
81243
Participant_Condition
hypertensive